Search by PDB author

Apo Estrogen Receptor Alpha Ligand Binding Domain D538G Mutant with a glucocorticoid receptor-interacting protein 1 NR box II peptide
Descriptor:	Estrogen receptor, Glucocorticoid receptor-interacting protein 1 NR box II peptide
Authors:	Fanning, S.W, Panchamukhi, S, Greene, G.L.
Deposit date:	2014-04-02
Release date:	2015-04-08
Last modified:	2024-02-28
Method:	X-RAY DIFFRACTION (2.24 Å)
Cite:	Estrogen receptor alpha somatic mutations Y537S and D538G confer breast cancer endocrine resistance by stabilizing the activating function-2 binding conformation. Elife, 5, 2016

The Estrogen Receptor Alpha Ligand Binding Domain D538G Mutant in Complex with Estradiol and a glucocorticoid receptor-interacting protein 1 NR box II peptide
Descriptor:	ESTRADIOL, Estrogen receptor, Nuclear receptor coactivator 2
Authors:	Fanning, S.W, Panchamukhi, S, Greene, G.L.
Deposit date:	2014-03-24
Release date:	2015-04-08
Last modified:	2024-02-28
Method:	X-RAY DIFFRACTION (1.9 Å)
Cite:	Estrogen receptor alpha somatic mutations Y537S and D538G confer breast cancer endocrine resistance by stabilizing the activating function-2 binding conformation. Elife, 5, 2016

The Estrogen Receptor Alpha Ligand Binding Domain D538G Mutant in Complex with 4-hydroxytamoxifen
Descriptor:	4-HYDROXYTAMOXIFEN, Estrogen receptor, SULFATE ION
Authors:	Fanning, S.W, Greene, G.L.
Deposit date:	2014-04-15
Release date:	2015-04-15
Last modified:	2024-02-28
Method:	X-RAY DIFFRACTION (3.07 Å)
Cite:	Estrogen receptor alpha somatic mutations Y537S and D538G confer breast cancer endocrine resistance by stabilizing the activating function-2 binding conformation. Elife, 5, 2016

Estrogen Receptor Alpha Ligand Binding Domain in Complex with Bazedoxifene
Descriptor:	Bazedoxifene, Estrogen receptor
Authors:	Fanning, S.W, Mayne, C.G, Toy, W, Carlson, K, Greene, B, Nowak, J, Walter, R, Panchamukhi, S, Tajhorshid, E, Nettles, K.W, Chandarlapaty, S, Katzenellenbogen, J, Greene, G.L.
Deposit date:	2015-01-06
Release date:	2016-01-13
Last modified:	2024-03-06
Method:	X-RAY DIFFRACTION (2.491 Å)
Cite:	The SERM/SERD bazedoxifene disrupts ESR1 helix 12 to overcome acquired hormone resistance in breast cancer cells. Elife, 7, 2018